Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process development—enhancing its capabilities in monoclonal antibody (mAb) development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to large-scale manufacturing.

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. By incorporating Breez into its process development, Celonic aims to accelerate upstream process optimization while reducing cost of goods per gram and increasing operational efficiency.

“This technology integration marks a significant milestone in our pursuit of innovative bioprocessing solutions,” said Samanta Cimitan Ph.D., CEO of Celonic Group. “By leveraging the Breez platform, we can enhance our ability to develop and manufacture biologics with the aim of increasing productivity, reducing the cost of goods per gram ultimately benefiting our clients and patients worldwide.”

More Celonic News

In February, Celonic Group signed a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for Commercial Supply.